The company said, “RXO expects third-quarter 2025 adjusted EBITDA to be between $33 million and $43 million. In Brokerage, the company expects overall volume growth to be approximately flat year-over-year and gross margin to be between 13.5% and 15.0% in the third quarter.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXO:
- RXO Inc. price target raised to $20 from $18 at Truist
- RXO Inc. price target lowered to $14 from $15 at JPMorgan
- RXO Inc. price target lowered to $21 from $23 at Morgan Stanley
- RXO, Inc. Faces Mixed Performance and Regulatory Challenges: Hold Rating with Cautious Outlook
- RXO Inc. price target raised to $12 from $10 at Susquehanna